A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in NMIBC

Non-Muscle-Invasive Bladder Cancer (NMIBC) Clinical Trial

Official title:

An Open-Label, Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination With BCG in Non-Muscle-Invasive Bladder Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06186414
• Other study ID #: SIM0237-102
• Status: Recruiting
• Phase: Phase 1
• Start date: January 23, 2024
• Est. completion date: December 2030

Study information

• Verified date: January 2024
• Source: Jiangsu Simcere Pharmaceutical Co., Ltd.
• Contact: Tammy Wu, Ph.D
• Phone: 13671827233
• Email: wutao[@]zaiming.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicenter phase 1 study to evaluate the safety, efficacy, and pharmacokinetics (PK) characteristics of SIM0237 alone or in combination with bacillus Calmette-Guerin (BCG) in participants with Non-Muscle-Invasive Bladder Cancer (NMIBC)

Description:

The study starts with a dose escalation part followed by a dose expansion part. The primary objective of the dose escalation part is to evaluate the safety and tolerability of SIM0237 alone or in combination with BCG, and determine the recommended dose(s) (RD). The primary objective of the dose expansion part is to evaluate the preliminary efficacy of SIM0237 alone or in combination with BCG.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 108
• Est. completion date: December 2030
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Written informed consent.
• = 18 years of age, male or female.
• Histologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1 disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1 disease. Histologic confirmation of urothelial carcinoma (mixed histology tumors allowed if urothelial histology is predominant histology).
• Dose escalation phase: BCG-unresponsive high-risk NMIBC.
• Dose expansion phase: a) Cohorts 1 and 2: BCG-unresponsive CIS (with or without Ta or T1 disease); b) Cohort 3: BCG-unresponsive high-risk Ta or T1 disease.
• Absence of resectable disease after transurethral resection (TURBT) procedures [residual carcinoma in situ (CIS) acceptable]. patients with T1 tumors must undergo repeat resection and biopsy if initial biopsy did not include muscularis propria, to ensure the inclusive of muscularis propria and the absence of invasive tumor.
• Not suitable for or unwilling to undergo radical cystectomy.
• ECOG performance status of 0, 1or 2.
• Life expectancy = 2 years.
• Adequate hematologic and organ function.
• Women of childbearing potential (WOCBP) must have a negative serum pregnancy test. WOCBP and male subjects agree to use adequate contraception.
• Tumor tissue (archival or fresh) for biomarker analysis.

Exclusion Criteria:

• Subjects received TURBT or other surgical treatment for bladder lesions or pelvic radiotherapy within 2 weeks prior to the first dose.
• Previous treatment with: a) Systematic drug administration for the purpose of treating NMIBC. b) Intravesical instillation for the treatment of NMIBC, but intravesical instillation of chemotherapy or BCG therapy beyond 4 weeks prior to the first dose and a single immediate instillation of chemotherapy within 4 weeks prior to the first dose are allowed. c) Intravesical instillation of mucosal protective agents (e.g., sodium hyaluronate) are allowed.
• Subject is participating in an investigational drug or investigational device study.
• Subjects have not recovered from AEs caused by previous anti-tumor treatment.
• History/evidence of prior muscle-invasive, locally advanced, metastatic bladder cancer or upper urinary tract (kidney, renal pelvis, ureter) and prostatic urethral tumors; Patients may be considered for enrollment if they have only upper urinary tract Ta/T1/CIS and have undergone radical nephrectomy more than 2 years prior to the first dose.
• Patients with other malignancies within 5 years before the first dose.
• Any active infection or urinary tract infection requiring systemic treatment by intravenous infusion within 2 weeks before the first dose.
• Subjects with clinically significant cardiovascular disease within 6 months before the first dose of study treatment.
• Known human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
• Active or chronic hepatitis B or hepatitis C infection.
• Known or suspected active autoimmune diseases.
• Concurrent use of any other anticancer therapy or chronic use of systemic corticosteroids at immunosuppressive doses (more than 10 mg/day prednisone or equivalent).
• History of pneumonitis or interstitial lung disease or severe obstructive pulmonary disease that requires oral or intravenous steroids to help recover.
• Known to be allergic or intolerant to study drugs, monoclonal antibodies, excipients; or allergic or intolerant to BCG (only for subjects receiving combined BCG therapy)
• Subjects discontinued prior BCG treatment due to AEs such as toxemia, systemic infection, or urinary incontinence (only for subjects receiving combined BCG therapy).
• History of allogeneic organ transplantation or graft-versus-host disease.
• Any live vaccines within 4 weeks before the first dose.
• Known mental illness or substance abuse that would interfere with trial complies.
• Subject is pregnant or lactating, or is expected to become pregnant or parent a child during the planned study period.
• Other conditions that investigators consider inappropriate for inclusion.

Related Conditions & MeSH terms

• Non-Muscle-Invasive Bladder Cancer (NMIBC)
• Urinary Bladder Neoplasms

Intervention

Drug:
• SIM0237
Several dose levels of SIM0237 will be administered as a single agent for evaluation
• SIM0237 and BCG
Several dose levels of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation
• SIM0237
RD level of SIM0237 will be administered as a single agent for evaluation
• SIM0237 and BCG
RD level of SIM0237 will be administered in combination with a fixed dose of BCG for evaluation

Locations

Country	Name	City	State
China	Peking University Third Hospital	Beijing	Beijing
China	Hunan Cancer Hospital	Changsha	Hunan
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong
China	The Affiliated Hospital of Qingdao University	Qingdao	Shandong
China	Fudan University Shanghai Cancer Center	Shanghai	Shanghai
China	The Second Hospital of Tianjin Medical University	Tianjin	Tianjin
China	Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University	Zhengzhou	Henan

Sponsors (2)

Lead Sponsor	Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd.	Shanghai Xianxiang Medical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose escalation:Dose limited toxicity (DLT)		DLT observation period (up to 21 days)
Primary	Dose escalation: Percentage of participants experiencing treatment-emergent adverse events (TEAEs)	Incidence and severity of adverse events (AEs) and serious adverse events(SAEs),and lab abnormalities	through study completion, an average of 5 years
Primary	Dose expansion:Complete response (CR) rate at Month 3	Complete response (CR) rate at Month 3 of Cohort 1 and Cohort 2	Approximately 3 months
Primary	Dose escalation: Percentage of participants experiencing AE related dose interruptions and dose delays, dose intensity	Occurrence of AE related dose interruptions, dose delays and dose intensity	through study completion, an average of 5 years